Methods and compositions for treating malaria
AssigneeCyvax, Inc.
InventorRichard Markham
Life of this patent
Estimating the term…
Abstract
Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3α, and an adjuvant. The antigen can be from a bacteria, virus, fungus, parasite, or cancer. The antigen can be an Alzheimer's disease antigen.
Claims2
A pharmaceutical composition comprising:
- (a.) a plasmid comprising a nucleic acid sequence consisting of the nucleotide sequence as set forth in SEQ ID NO:31;
- and (b.) a liposome adjuvant comprising a commixture of (±)-N-(3-aminopropyl)-N,N-dimethyl-2,3-bis(cis-9-tetradecenyloxy) -1-propanaminium bromide (GAP-DMORIE) and 1,2-diphytanoyl-sn-glycero-3-phosphoethanolamine (DPyPE).
A method for eliciting an immune response in a subject comprising administering to the subject a pharmaceutical composition comprising a nucleic acid sequence encoding a parasite antigen or fragment thereof fused to an immune cell product.
Dependencies are inferred from the claim text.